Project Grant R01CA295696
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$631K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) provides funding to Ampedrna Biosciences LLC to develop a highly immunogenic mini-circular RNA (mRNA) vaccine for human papillomavirus (HPV)-related cancers. The award, totaling $398,823, supports research to demonstrate the superior efficacy of a multivalent mRNA HPV16 E6/E7 vaccine compared to a benchmark mRNA vaccine. Key objectives include showing that the mRNA vaccine can...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,288,122 to New York University (NYU) from June 1, 2024 to May 31, 2029. The project aims to identify modifiable multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. Key activities include:
Collecting primary qualitative and quantitative data, as well as analyzing secondary quantitative data, on factors affecting HPV vaccine uptake at the...
The National Cancer Institute (NCI) awarded a $1,224,998 Cooperative Agreement (CFDA 93.393 Cancer Cause and Prevention Research) to New York University to implement the KUPEWA project. The project aims to identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for adolescent girls and young women living with HIV in Malawi. Key activities include refining an evidence-based set of implementable strategies, conducting an intervention optimization...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will provide $191,700 to Northwestern University to develop and test a culturally-relevant digital health intervention targeting HPV vaccination among the U.S. Vietnamese population. The study, titled "HPV Education & Resources for the U.S. Vietnamese Population (HERO)," will leverage the Multiphase Optimization Strategy (MOST) framework to assess the feasibility, acceptability,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) provides $184,528 to Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of Cleveland) to conduct research on antibody-bound vaginal bacteria associated with HPV infection and cervical dysplasia. The overarching goal is to define the relationships between the proportion, abundance, and functional...
This federal Project Grant award in the amount of $446,728 was made by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The award supports research to understand the viral and host factors involved in Juvenile-Onset Recurrent Respiratory Papillomatosis (JORRP), a rare and debilitating childhood disease caused by low-risk HPV viruses. The research aims to develop new biomarkers and therapeutic approaches for JORRP by leveraging novel 2D and 3D...
This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program.
The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $544,768 to the University of New Mexico Health Sciences Center (UNM HSC) to support research on the mechanisms of papillomavirus tumor regression through MEK signaling inhibition. The project aims to investigate how MEK inhibition reduces papillomavirus oncogene expression, leading to decreased keratinocyte proliferation and activation of innate immune responses to...
The National Cancer Institute (NCI) awarded a $233,411 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Pennsylvania State University (Penn State) to evaluate the impact of a narrative communication intervention delivered through digital and mobile technology on human papillomavirus (HPV) vaccine initiation rates among children ages 9-12. The 2-year grant, effective April 1, 2025, aims to understand how narrative communication influences parents' HPV...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395), supports a two-center Phase II clinical trial of E7 TCR-T cell therapy for the treatment of metastatic HPV-associated cancers. The award provides $642,086 in funding from August 1, 2024 through July 31, 2028.
The trial will be conducted by Rutgers, The State University of New Jersey, and will leverage the university's expertise in novel...